FDA isn't recommending label change for ADHD drugs

04/10/2011 | Reuters

The FDA is not requiring drugmakers to change usage and safety information for Shire's Adderall XR, Novartis' Ritalin and other stimulants for attention-deficit/hyperactivity disorder. The agency said it will provide an update after it finishes analyzing ADHD drugs' potential risk of cardiovascular events.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC